Enhanced Antitumor Efficacy of Fiber-modified, Midkine Promoter-regulated Oncolytic Adenovirus in Human Malignant Mesothelioma

Overview

Journal Cancer Sci

Specialty Oncology

Date 2013 Aug 22

PMID 23962292

Citations 18

Authors

Misato Takagi-Kimura

Tomoki Yamano

Atsuko Tamamoto

Nobutaka Okamura

Haruki Okamura

Tomoko Hashimoto-Tamaoki

Masatoshi Tagawa

Noriyuki Kasahara

Shuji Kubo

Affiliations

Soon will be listed here.

Abstract

Oncolytic virotherapy using adenoviruses has potential for therapeutic benefits in malignant mesothelioma. However, the downregulation of coxsackie virus/adenovirus receptor (CAR) expression is frequently a critical rate-limiting factor that impedes the effectiveness of adenovirus serotype 5 (Ad5)-based vectors in many cancer types. We evaluated CAR (Ad5 receptor) and CD46 (adenovirus serotype 35 [Ad35] receptor) expression in six human malignant mesothelioma cell lines. Very low CAR expression was observed in MSTO-211H and NCI-H2052 cells, whereas the other cell lines showed strong expression. In contrast, CD46 was highly expressed in all mesothelioma cell lines. On this basis, we replaced the CAR binding sequence of Ad5 with the CD46 binding sequence of Ad35 in the replication-defective adenoviruses and the tumor-specific midkine promoter-regulated oncolytic adenoviruses. By this fiber modification, the infectivity, virus progeny production, and in vitro cytocidal effects of the adenoviruses were significantly enhanced in low CAR-expressing MSTO-211H and NCI-H2052 cells, also resulting in similar or even higher levels in high CAR-expressing mesothelioma cell lines. In MSTO-211H xenograft models, the fiber-modified oncolytic adenovirus significantly enhanced antitumor effect compared to its equivalent Ad5-based vector. Our data demonstrate that Ad35 fiber modification of binding tropism in a midkine promoter-regulated oncolytic Ad5 vector confers transductional targeting to oncolytic adenoviruses, thereby facilitating more effective treatment of malignant mesothelioma.

Citing Articles

Biological basis for novel mesothelioma therapies.

Obacz J, Yung H, Shamseddin M, Linnane E, Liu X, Azad A Br J Cancer. 2021; 125(8):1039-1055.

PMID: 34226685 PMC: 8505556. DOI: 10.1038/s41416-021-01462-2.

Immunotherapy for mesothelioma: a critical review of current clinical trials and future perspectives.

Gray S, Mutti L Transl Lung Cancer Res. 2020; 9(Suppl 1):S100-S119.

PMID: 32206576 PMC: 7082257. DOI: 10.21037/tlcr.2019.11.23.

The Oncolytic Virus 922-947 Triggers Immunogenic Cell Death in Mesothelioma and Reduces Xenograft Growth.

Di Somma S, Iannuzzi C, Passaro C, Forte I, Iannone R, Gigantino V Front Oncol. 2019; 9:564.

PMID: 31355131 PMC: 6639422. DOI: 10.3389/fonc.2019.00564.

Combination therapy with F5/35 fiber chimeric conditionally replicative adenoviruses expressing IL-24 enhances the antitumor effect of temozolomide against melanoma.

Yang M, Yang C, Tao Y, Tang J, Huang Q, Guo W Cancer Med. 2018; 7(12):5928-5942.

PMID: 30406970 PMC: 6308089. DOI: 10.1002/cam4.1843.

Targeting CD46 Enhances Anti-Tumoral Activity of Adenovirus Type 5 for Bladder Cancer.

Do M, To P, Cho Y, Kwon S, Hwang E, Choi C Int J Mol Sci. 2018; 19(9).

PMID: 30201920 PMC: 6164063. DOI: 10.3390/ijms19092694.

References

Aridome K, Tsutsui J, Takao S, Kadomatsu K, Ozawa M, Aikou T . Increased midkine gene expression in human gastrointestinal cancers. Jpn J Cancer Res. 1995; 86(7):655-61. PMC: 5920887. DOI: 10.1111/j.1349-7006.1995.tb02449.x. View

Kaname T, Kadomatsu K, Aridome K, Yamashita S, Sakamoto K, Ogawa M . The expression of truncated MK in human tumors. Biochem Biophys Res Commun. 1996; 219(1):256-60. DOI: 10.1006/bbrc.1996.0214. View

Bergelson J, Cunningham J, Droguett G, Krithivas A, Hong J, Horwitz M . Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science. 1997; 275(5304):1320-3. DOI: 10.1126/science.275.5304.1320. View

Gaggar A, Shayakhmetov D, Liszewski M, Atkinson J, Lieber A . Localization of regions in CD46 that interact with adenovirus. J Virol. 2005; 79(12):7503-13. PMC: 1143628. DOI: 10.1128/JVI.79.12.7503-7513.2005. View

Yu L, Shimozato O, Li Q, Kawamura K, Ma G, Namba M . Adenovirus type 5 substituted with type 11 or 35 fiber structure increases its infectivity to human cells enabling dual gene transfer in CD46-dependent and -independent manners. Anticancer Res. 2007; 27(4B):2311-6. View

Kubo S, Kawasaki Y, Yamaoka N, Tagawa M, Kasahara N, Terada N . Complete regression of human malignant mesothelioma xenografts following local injection of midkine promoter-driven oncolytic adenovirus. J Gene Med. 2010; 12(8):681-92. PMC: 2938764. DOI: 10.1002/jgm.1486. View

Kadomatsu K, Muramatsu T . Midkine and pleiotrophin in neural development and cancer. Cancer Lett. 2004; 204(2):127-43. DOI: 10.1016/S0304-3835(03)00450-6. View

Ismail-Khan R, Robinson L, Williams Jr C, Garrett C, Bepler G, Simon G . Malignant pleural mesothelioma: a comprehensive review. Cancer Control. 2006; 13(4):255-63. DOI: 10.1177/107327480601300402. View

Owada K, Sanjo N, Kobayashi T, Mizusawa H, Muramatsu H, Muramatsu T . Midkine inhibits caspase-dependent apoptosis via the activation of mitogen-activated protein kinase and phosphatidylinositol 3-kinase in cultured neurons. J Neurochem. 1999; 73(5):2084-92. View

10.

Tagawa M, Tada Y, Shimada H, Hiroshima K . Gene therapy for malignant mesothelioma: current prospects and challenges. Cancer Gene Ther. 2013; 20(3):150-6. DOI: 10.1038/cgt.2013.1. View

11.

Tsao A, Wistuba I, Roth J, Kindler H . Malignant pleural mesothelioma. J Clin Oncol. 2009; 27(12):2081-90. PMC: 4881753. DOI: 10.1200/JCO.2008.19.8523. View

12.

Kojima S, Inui T, Muramatsu H, Kimura T, Sakakibara S, Muramatsu T . Midkine is a heat and acid stable polypeptide capable of enhancing plasminogen activator activity and neurite outgrowth extension. Biochem Biophys Res Commun. 1995; 216(2):574-81. DOI: 10.1006/bbrc.1995.2661. View

13.

Choudhuri R, Zhang H, Donnini S, Ziche M, Bicknell R . An angiogenic role for the neurokines midkine and pleiotrophin in tumorigenesis. Cancer Res. 1997; 57(9):1814-9. View

14.

Ranki T, Hemminki A . Serotype chimeric human adenoviruses for cancer gene therapy. Viruses. 2011; 2(10):2196-2212. PMC: 3185575. DOI: 10.3390/v2102196. View

15.

Mashour G, Ratner N, Khan G, Wang H, Martuza R, Kurtz A . The angiogenic factor midkine is aberrantly expressed in NF1-deficient Schwann cells and is a mitogen for neurofibroma-derived cells. Oncogene. 2001; 20(1):97-105. DOI: 10.1038/sj.onc.1204026. View

16.

Kim M, Zinn K, Barnett B, Sumerel L, Krasnykh V, Curiel D . The therapeutic efficacy of adenoviral vectors for cancer gene therapy is limited by a low level of primary adenovirus receptors on tumour cells. Eur J Cancer. 2002; 38(14):1917-26. DOI: 10.1016/s0959-8049(02)00131-4. View

17.

Miyauchi M, Shimada H, Kadomatsu K, Muramatsu T, Matsubara S, Ikematsu S . Frequent expression of midkine gene in esophageal cancer suggests a potential usage of its promoter for suicide gene therapy. Jpn J Cancer Res. 1999; 90(4):469-75. PMC: 5926091. DOI: 10.1111/j.1349-7006.1999.tb00771.x. View

18.

Kadomatsu K, Hagihara M, Akhter S, Fan Q, Muramatsu H, Muramatsu T . Midkine induces the transformation of NIH3T3 cells. Br J Cancer. 1997; 75(3):354-9. PMC: 2063356. DOI: 10.1038/bjc.1997.58. View

19.

Yu L, Takenobu H, Shimozato O, Kawamura K, Nimura Y, Seki N . Increased infectivity of adenovirus type 5 bearing type 11 or type 35 fibers to human esophageal and oral carcinoma cells. Oncol Rep. 2005; 14(4):831-5. View

20.

Kinugasa N, Higashi T, Nouso K, Nakatsukasa H, Kobayashi Y, Ishizaki M . Expression of membrane cofactor protein (MCP, CD46) in human liver diseases. Br J Cancer. 1999; 80(11):1820-5. PMC: 2374269. DOI: 10.1038/sj.bjc.6690604. View